Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium

NCT01090466 is registered in ClinicalTrials.gov with Cardiff University as lead sponsor.

NCT NCT01090466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01090466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium
Lead sponsor
Cardiff University
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2008
Completion date
March 16, 2016
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer